CRISPR Therapeutics Appoints Andrew J. Silver as Chief Financial Officer
Position
Principal
Company
Crispr Therapeutics
ZugBiotechnologyHealthcareHealth CareGeneticsTherapeuticsDescription
CRISPR Therapeutics AG has announced the promotion of Andrew J. Silver to Chief Financial Officer effective immediately as of October 19, 2026. Mr
Quick answer
CRISPR Therapeutics Appoints Andrew J. Silver as Chief Financial Officer (October 19, 2026). Crispr Therapeutics is based in Zug, Zug, Switzerland.
- Who is the new Principal at Crispr Therapeutics?
- Crispr Therapeutics named Andrew J. Silver Principal, announced October 19, 2026.
- What did Crispr Therapeutics announce on October 19, 2026?
- CRISPR Therapeutics AG has announced the promotion of Andrew J. Silver to Chief Financial Officer effective immediately as of October 19, 2026.
- What does Crispr Therapeutics do?
- CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
- Where is Crispr Therapeutics based?
- Crispr Therapeutics is based in Zug, Zug, Switzerland.
- Which similar companies made leadership changes around the same time?
- CytoDyn (October 19, 2026), Tempest Therapeutics (October 19, 2026), Genetix Biotherapeutics (October 19, 2026) and Gyre Therapeutics (October 22, 2026) also announced leadership changes within 45 days of Crispr Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Healthcare and Genetics
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- CytoDyn Inc. Appoints Robert E. Hoffman as CEO (October 19, 2026)
- Tempest Therapeutics Appoints John Frederick as Class III Director (October 19, 2026)
- Genetix Biotherapeutics Appoints Meredith Manning as Chief Commercial Officer (October 19, 2026)
- Gyre Therapeutics Appoints Ying Luo as CEO and Thomas Eastling as CFO (October 22, 2026)
- Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer (October 23, 2026)
- Enliven Therapeutics Appoints Kristine Ball as Class II Director (October 14, 2026)
Who to call at Crispr Therapeutics, and when
A new leader at Crispr Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Crispr Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Crispr Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Crispr Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Crispr Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Crispr Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.